Skip to content

EACS: Once-a-day Kaletra can be risky

ICAAC: No drug interactions found between TMC125 and ritonavir-boosted elvitegravir

ICAAC: In NNRTI-based regimens, stepwise discontinuation minimises risk of antiretroviral resistance

IAS: Studies present reassuring data on the use of ART in patients on TB treatment

IAS: Botswanan study finds low concentrations of TB drugs common in HIV-positives, predict TB treatment failure

Pfizer advises maraviroc dose increase if combined with etravirine

Study suggests many children could have subtherapeutic levels of efavirenz

CROI: Therapeutic concentrations of efavirenz, Kaletra, could be difficult to achieve in some children, with or without rifampicin

Severe interaction between low-dose ritonavir and a blood pressure drug observed